Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond

SEATTLE, May 04, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced seven presentations from across its technology platforms to be featured at the 26th American Society for Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 16-20 in Los Angeles, CA. The featured presentations include new data from the company’s RNAfix®, RNAswap™, AAVid™, and TruStable™ platforms.

Additionally, ShapeTX will host an industry-sponsored symposium entitled, “Advancing Programmable Medicine Through AAVid Capsid Engineering and TruStable Cell Line Manufacturing” on Thursday, May 18 in Petree Hall D, 12:00-1:30 pm. 

“The breadth of data to be presented at ASGCT demonstrates our leadership in the field of gene therapy and highlights the arsenal of disruptive technologies we’ve built,” said Francois Vigneault, Ph.D., co-founder and CEO at ShapeTX. “By integrating massive parallel biological screens, advanced bioinformatics, and generative deep learning models with RNA technologies, we are accelerating drug discovery for previously untreatable diseases.”
  
The presentations are listed below and the full abstracts are available on the ASGCT meeting website. All times are listed in Pacific Time (PT).

Wednesday, May 17: 

  • Rational Engineering of Novel Synthetic Promoters for Specific AAV-Delivered GRN Expression in the CNS
    Abstract number: 379
    Time: 12:00 PM 
    Type: Poster Session
  • Generative Machine Learning Enables De Novo Guide RNA Design for Precise RNA Editing
    Abstract number: 517
    Time: 12:00 PM
    Type: Poster Session

Thursday, May 18: 

  • Long Read Sequencing of rAAV Vectors Illuminates Origins of Contaminating Genomic Species
    Abstract number: 178
    Time: 5:15 PM - 5:30 PM (Concourse Hall 150-151)
    Type: Oral Abstract Session
    Session: AAV Vector Genome Biology and Engineering I
  • TruStable™: A Fully Integrated Inducible Stable Producer Cell Line for AAV Manufacturing
    Abstract number: 828
    Time: 12:00 PM
    Type: Poster Session

Saturday, May 20: 

  • Massive Diversity Capsid Screening and Machine Learning Identify Next-Generation AAV for Targeted Tissue Biodistribution
    Abstract number: 327
    Time: 8:00 AM - 8:15 AM (Concourse Hall 150-151)
    Type: Oral Abstract Session
    Session: AAV Development for Eye, Muscle, Kidney and CNS
  • Novel Engineered U7 Small Nuclear RNA (snRNA) Scaffold Increases ADAR-Mediated Programmable RNA Base Editing
    Abstract number: 333
    Time: 8:00 AM - 8:15 AM (Concourse Hall 152 & 153)
    Type: Oral Abstract Session
    Session: Genome & Epigenome Editing Technologies II
  • High Efficiency In Vivo RNA Editing in the CNS with AAV-Delivered ADAR gRNAs
    Abstract number: 347
    Time: 8:00 AM - 8:15 AM (Room 515 AB)
    Type: Oral Abstract Session
    Session: Gene Targeting and Gene Correction: CNS

About ShapeTX
ShapeTX is pioneering programmable RNA medicines to repair the genetic causes of disease. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more. You can find us at ShapeTX.com and on LinkedIn and Twitter.  

Investor and Media Contact
Cindy Fung, PhD
cindy@shapetx.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.